Phaseline

Companies › iLeukon Therapeutics

iLeukon Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Jun 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ILKN421H–Phase 2Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Jun 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07452224ILKN421HPhase 2Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)OncologyJun 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Vasgene Therapeutics Suzhou BlueHorse Therapeutics Pieris Pharmaceuticals Evaxion Biotech Primmune Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.